February 03, 2022 – ZURICH – Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced that they now offer near-complete quantification of tissue proteomes, visualizing up to 13,000 of the proteins expressed in human tissue with their Tissue Biomarker Discovery research service.
As the leading service provider for tissue proteomics, Biognosys goes far beyond simply measuring proteins granting the most complete peptide-level data readout and most actionable multi-dimensional insights on protein expression, function, and structure, including PTMs. In this way, Biognosys helps unlock the deepest biological insights for drug research and development.
“Our latest discovery technology improvements enable deep, single-shot profiling of human tissue proteomes, quantifying up to 90% of the expressed proteins. Our contract research services now offer a depth of 13,000 proteins in lung cancer, for example.”
In a recent lung cancer pilot study, the Biognosys contract research operation department identified and quantified a record number of 13,187 protein groups with their next-generation single-shot proteomics technology, HRM™. The depth of analysis goes beyond what was achieved in the Deep Human Proteome Atlas (deep fractionated tissue with multiple MS acquisitions, Wang et at. 2019, Mol Syst Biol).
Interestingly, 414 oncogenes, 392 transcription factors, 837 plasma membrane proteins (25 GPCR), and 316 kinases covering a dynamic range of 10 were identified. In addition, 0.25 Mio peptides (including modifications and charge state) were measured in the totality. And the cancer types could be separated by PCA, and X proteins were significantly differential abundant. To our knowledge, this represents the deepest single shot proteome profiling reported to date.
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
Biognosys AG
Wagistrasse 21
8952 Schlieren
Switzerland
Phone: +41 44 738 20 40
US Offices
Biognosys Inc
70 Bridge St, Suite 104
Newton, MA 02458
United States
